Follow
Joaquin Portilla
Joaquin Portilla
Profesor de Medicina, Universidad Miguel Hernández
Verified email at umh.es
Title
Cited by
Cited by
Year
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
4042019
Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE …
S Walmsley, A Baumgarten, J Berenguer, F Felizarta, E Florence, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 70 (5), 515-519, 2015
2852015
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of …
J Van Wyk, F Ajana, F Bisshop, S De Wit, O Osiyemi, J Portilla Sogorb, ...
Clinical Infectious Diseases 71 (8), 1920-1929, 2020
2602020
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse …
JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ...
The Lancet Infectious Diseases 15 (7), 785-792, 2015
1942015
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
F Pulido, JR Arribas, R Delgado, E Cabrero, J González-García, ...
Aids 22 (2), F1-F9, 2008
1942008
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority …
JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ...
The lancet HIV 5 (5), e211-e220, 2018
1642018
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
JR Arribas, R Delgado, A Arranz, R Muñoz, J Portilla, J Pasquau, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (2), 147-152, 2009
1452009
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated …
C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ...
The Lancet HIV 4 (12), e536-e546, 2017
1382017
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat …
C Orkin, JM Molina, E Negredo, JR Arribas, J Gathe, JJ Eron, ...
The Lancet HIV 5 (1), e23-e34, 2018
1282018
Dyslipidemia related to antiretroviral therapy.
V Estrada, J Portilla
AIDS reviews 13 (1), 49-56, 2011
1242011
Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain
N Merchante, E Merino, J López-Aldeguer, F Jover, ...
Clinical Infectious Diseases 56 (1), 143-150, 2013
952013
Low-level HIV viremia is associated with microbial translocation and inflammation
S Reus, J Portilla, J Sánchez-Payá, L Giner, R Francés, J Such, V Boix, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (2), 129-134, 2013
912013
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
F Pulido, I Pérez-Valero, R Delgado, A Arranz, J Pasquau, J Portilla, ...
Antiviral therapy 14 (2), 195-201, 2009
832009
Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic suppression in …
O Osiyemi, S De Wit, F Ajana, F Bisshop, J Portilla, JP Routy, C Wyen, ...
Clinical Infectious Diseases 75 (6), 975-986, 2022
702022
Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population
J Murcia, P Llorens, J Sánchez-Payá, S Reus, V Boix, E Merino, ...
Journal of Infection 61 (6), 458-464, 2010
692010
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 …
JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ...
The lancet HIV 7 (1), e16-e26, 2020
632020
Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort
M Torres, C González, J del Romero, P Viciana, A Ocampo, ...
Journal of Clinical Microbiology 51 (11), 3512-3520, 2013
622013
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics
J Berenguer, A Rivero, I Jarrín, MJ Núñez, MJ Vivancos, M Crespo, ...
Open forum infectious diseases 3 (2), ofw059, 2016
612016
Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions
M Paz-Zulueta, L Álvarez-Paredes, JC Rodríguez Díaz, P Parás-Bravo, ...
BMC cancer 18, 1-9, 2018
582018
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy
J Berenguer, B Alejos, V Hernando, P Viciana, M Salavert, I Santos, ...
Aids 26 (17), 2241-2246, 2012
572012
The system can't perform the operation now. Try again later.
Articles 1–20